By admin 
Lipoprotein(a), often pronounced "LP-little-a," is a particle in the blood that carries cholesterol, similar to low-density lipoprotein (LDL), but with an added protein called apolipoprotein(a). This extra protein makes the particle more "sticky," promoting the formation of blood clots and accelerating the buildup of arterial plaque (atherosclerosis). Unlike LDL cholesterol, which can fluctuate based on lifestyle choices and age, Lp(a) levels are almost entirely determined by an individual’s genetics. Approximately one in five people worldwide possess elevated levels of Lp(a), putting them at a significantly higher risk for heart attacks, strokes, and aortic stenosis, often at a young age and despite having otherwise healthy cholesterol profiles. Because traditional lipid-lowering therapies have negligible effects on Lp(a), the medical community has eagerly anticipated a new class of "genetic medicines" designed to silence the LPA gene.
Pelacarsen, an antisense oligonucleotide (ASO) originally developed by Ionis Pharmaceuticals and licensed to Novartis in a deal worth over $1 billion in potential milestones, was designed to do exactly that. By targeting the messenger RNA (mRNA) responsible for producing apolipoprotein(a) in the liver, the drug had demonstrated the ability to reduce circulating Lp(a) levels by 80% or more in earlier, mid-stage clinical trials. The Phase 3 HORIZON trial was the definitive test, a massive undertaking that enrolled approximately 8,300 patients across dozens of countries. These participants all had established cardiovascular disease and baseline Lp(a) levels of at least 70 mg/dL, a threshold considered high enough to drive significant risk. The study’s primary goal was to determine if pelacarsen could reduce a composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and urgent coronary revascularization.
The failure of the HORIZON trial to achieve statistical significance on this primary endpoint is a staggering result for Novartis. In a brief statement, the company acknowledged that while the drug successfully lowered Lp(a) levels as expected, that reduction did not manifest as a clinical benefit for the patients involved. This discrepancy creates a "mechanistic gap" that researchers will be scrambling to explain in the coming months. It raises fundamental questions: Is Lp(a) merely a marker of risk rather than a direct cause of disease? Or was the trial design, patient selection, or duration insufficient to capture the benefits of lowering a lifelong genetic risk factor?
The fallout from this news extends far beyond Novartis’s headquarters in Basel. The spotlight now shifts to Amgen and Eli Lilly, both of which are deep into the development of their own Lp(a)-lowering agents. Amgen is currently conducting the Phase 3 VESUVIUS-CV trial for olpasiran, a small interfering RNA (siRNA) therapy. Unlike Novartis’s antisense approach, siRNA utilizes the body’s natural RNA interference pathway to degrade target mRNA with high precision and long-lasting effects, often requiring only a few injections per year. Similarly, Eli Lilly is advancing lepodisiran, another siRNA candidate that showed nearly 100% reduction in Lp(a) levels in early-stage trials.
Industry analysts are now debating whether these competing drugs will suffer the same fate as pelacarsen or if their different molecular mechanisms might yield a better clinical outcome. Some experts suggest that the "depth" of the knockdown matters; while pelacarsen reduces Lp(a) significantly, siRNA therapies like olpasiran and lepodisiran often achieve even more profound and sustained suppression. There is also the question of "residual risk." Many patients in the HORIZON trial were likely already on high-intensity statins and other therapies to manage their LDL cholesterol. It is possible that in the modern era of cardiovascular care, the incremental benefit of lowering Lp(a) is harder to prove than it would have been twenty years ago.
The history of cardiovascular drug development is littered with high-profile failures that initially showed great promise in lipid modulation. One notable example is the class of CETP inhibitors, such as Pfizer’s torcetrapib and Eli Lilly’s evacetrapib, which raised "good" HDL cholesterol to record levels but failed to prevent heart attacks, and in some cases, even increased mortality. Those failures taught the industry that changing a biomarker does not always change a patient’s destiny. However, the Lp(a) field was thought to be different because of the overwhelming genetic evidence linking high levels to disease. Mendelian randomization studies—which use genetic variants to simulate long-term clinical trials—have consistently suggested that lowering Lp(a) should provide a robust protective effect.
For Novartis, the failure of pelacarsen is a strategic hurdle. The company has been narrowing its focus to four core therapeutic areas, with cardiovascular disease being a primary pillar. Novartis already markets Entresto for heart failure and Leqvio (inclisiran), an siRNA drug for LDL cholesterol. Pelacarsen was expected to be the third "blockbuster" in this portfolio, providing a unique solution for a massive, underserved patient population. Without pelacarsen, Novartis may need to look toward external acquisitions to bolster its cardiovascular pipeline, or double down on its efforts to expand the indications for Leqvio.
The scientific community will now wait for the full data set from the HORIZON trial, which Novartis is expected to present at a major medical congress later this year. Researchers will look closely at subgroup analyses to see if specific types of patients—perhaps those with the highest baseline Lp(a) or those with the fewest other risk factors—did see some benefit. They will also examine the safety profile of the drug. While pelacarsen was generally considered safe, antisense oligonucleotides can sometimes cause injection-site reactions or transient drops in platelet counts, though it is unlikely that safety issues alone caused the trial’s failure.
Meanwhile, patient advocacy groups and cardiologists expressed disappointment at the news. For the millions of people who have been told they have high Lp(a) and that there is "nothing they can do about it," pelacarsen was a beacon of hope. The current standard of care for these patients involves managing every other modifiable risk factor to the extreme—driving LDL cholesterol as low as possible, controlling blood pressure, and ensuring perfect glucose management—to compensate for the "bad hand" they were dealt genetically. The search for a direct treatment continues, but the path forward has become considerably more complex.
As Amgen and Eli Lilly move forward with their respective programs, they will undoubtedly be scrutinizing the HORIZON data for clues. If the failure was due to the biology of Lp(a) itself, their programs may be in jeopardy. If, however, the failure was related to the specific potency or dosing of pelacarsen, there may still be a multi-billion-dollar market for a more effective drug. Other smaller players are also in the mix, such as Silence Therapeutics with its candidate muvalaplin, an oral small molecule that inhibits the formation of Lp(a) particles, and Arrowhead Pharmaceuticals, which is exploring various RNA-based approaches.
The cardiovascular field remains at a crossroads. The transition from broad-spectrum treatments like statins to precision, genetic-based therapies is fraught with challenges. While the failure of pelacarsen is a significant setback, it provides a crucial data point in the ongoing effort to understand the complexities of human lipid metabolism. The "Lp(a) story" is far from over, but the next chapters will require even more rigorous science and perhaps a rethinking of how we measure success in the fight against heart disease. For now, the industry watches and waits, hoping that the next generation of therapies can turn the tide where Novartis could not.
